Pure Red Cell Aplasia Stem Cell Therapy Development

Pure red cell aplasia (PRCA) is a syndrome defined by a normocytic normochromic anemia with severe reticulocytopenia and marked reduction or absence of erythroid precursors from the bone marrow. Stem cell therapy is a potential treatment option for PRCA, of which the goal is to replace the damaged bone marrow with healthy stem cells that can then develop into new red blood cells and restore normal blood cell production. CD BioSciences has launched a development service for stem cell therapy development for PRCA, dedicated to advance the treatment of PRCA.

Introduction into Pure Red Cell Aplasia

Pure red cell aplasia (PRCA) is a rare disorder in which the bone marrow fails to produce sufficient red blood cells (RBCs), resulting in anemia. It is called "pure" because other blood cell types such as white blood cells and platelets are usually unaffected. Pure red cell aplasia can be classified as primary or secondary based on the underlying cause. Primary PRCA is a rare congenital disorder that is usually diagnosed in infancy or early childhood, which is also called Diamond-Blackfan syndrome. It is caused by a genetic defect that affects the production of erythrocyte precursors in the bone marrow, leading to severe anemia.

Secondary PRCA, on the other hand, can develop later in life and can have a variety of causes. Some of the common causes of secondary PRCA include:

• Viral infections such as parvovirus B19, hepatitis C, and HIV
• Certain medications such as azathioprine, cyclosporine, and chloramphenicol
• Autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)
• Exposure to toxins such as benzene and lead
• Pregnancy is associated with PRCA, which usually (but not always) subsides after delivery
• ABO-incompatible stem cell transplantation, which is observed most commonly with the combination of a blood group A donor and a blood group O recipient

Pathogenesis of PRCA (Gurnari, et al., 2021)

Stem Cell Therapy for Pure Red Cell Aplasia

The treatment of PRCA depends on the underlying cause and severity of the anemia. Stem cell therapy is a potential treatment option for PRCA, particularly in cases where other treatments have not been successful. The goal of stem cell therapy is to replace the damaged bone marrow with healthy stem cells, which can then develop into new red blood cells and restore normal blood cell production.

Stem cells are unspecialized cells that have the ability to develop into different types of cells in the body. In the case of PRCA, stem cells from a healthy donor are used to replace the damaged bone marrow. This is done through a process called hematopoietic stem cell transplantation (HSCT), also known as a bone marrow transplant.

During an HSCT procedure, the patient receives high-dose chemotherapy or radiation therapy to destroy the existing bone marrow and any remaining cancer cells. This is followed by the infusion of healthy stem cells from a donor, which migrate to the bone marrow and begin producing new blood cells.

Our Services

Stem cell therapy is a potential treatment option for pure red cell aplasia, particularly in cases where other treatments have not been successful. Based on the advanced technology and professional team, CD BioSciences offers stem cell therapy development services for PRCA. The workflow of our service is as follows:

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

Reference

1. Gurnari, Carmelo, and Jaroslaw P Maciejewski. "How I manage acquired pure red cell aplasia in adults." Blood vol. 137,15 (2021): 2001-2009.